$VNDA

Vanda Pharmaceuticals (VNDA) reported that its Phase III study of VQW-765 for social anxiety disorder did not meet the primary endpoint, failing to show a significant difference from placebo. The study evaluated 546 adults and did not confirm earlier Phase II results. The company plans to analyze the full dataset before deciding next steps. VQW-765 is a novel alpha 7 nicotinic acetylcholine receptor partial agonist.

Vanda Pharmaceuticals (VNDA) completed a Phase 3 trial of tasimelteon for delayed sleep-wake phase disorder. The study, comparing the drug to a placebo, aims to improve sleep timing and assess safety. Positive results could expand tasimelteon's use and boost VNDA's revenue forecasts, though market reaction depends on detailed outcomes.

H.C. Wainwright reiterated a Buy rating and $20 price target for Vanda Pharmaceuticals (VNDA) after positive Phase 3 trial results for its sleep disorder treatment. The stock is down over 10% in the past week, trading at $4.63. The study met its primary endpoint, with HETLIOZ shifting sleep onset 42.5 minutes earlier vs. placebo. Vanda reported a disappointing Q2 2026, missing earnings and revenue estimates, with an adjusted loss of $1.04 per share and revenue of $50.5 million.

Vanda Pharmaceuticals (VNDA) reported positive late-stage trial results for Hetlioz in treating adults with delayed sleep-wake phase disorder, aiming for FDA label expansion.

Vanda Pharmaceuticals (VNDA) stock rose 12% in after-hours trading to $5.63 after reporting positive phase III results for its Hetlioz treatment in delayed sleep-wake phase disorder. The trial met its primary endpoint, and the company plans to discuss the data with the FDA. If approved, Hetlioz would be the first FDA-approved medicine for this condition.

Vanda Pharmaceuticals (VNDA) reported positive Phase III results for HETLIOZ® in treating Delayed Sleep-Wake Phase Disorder. The study showed a 37.1-minute earlier sleep onset vs. placebo. Vanda plans to submit an sNDA for this new indication, aiming to make HETLIOZ® the first FDA-approved treatment for the disorder.

Vanda Pharmaceuticals Inc. [VNDA] launched two new drugs, NEREUS and BYSANTI. BYSANTI's launch and a switch strategy from Fanapt are expected to drive near-term revenue. The company aims for $750 million in psychiatry revenue by 2030, supported by phase III readouts and product diversification, according to its 12th Annual Cantor Fitzgerald Global Healthcare Conference.

Vanda Pharmaceuticals (VNDA) outlined its growth plans at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, targeting $750M in psychiatry revenue by 2030. The company expects BYSANTI, approved for bipolar disorder and schizophrenia, to be a key catalyst with a favorable pricing structure. VNDA also highlighted its pipeline, including NEREUS for motion sickness and potential GLP-1-related nausea and vomiting. Fanapt, a current growth driver, has a 30% year-over-year growth rate. The

U.S. stock futures fell early Monday due to tariff uncertainty and Iran tensions. Nasdaq, S&P 500, and Dow futures declined 0.5%-0.6%. Nvidia's earnings, Netflix's board controversy, and Honeywell's acquisition are in focus. Precious metals rose, with gold above $5,100 and silver near $88/oz.

Vanda Pharmaceuticals (VNDA) announced FDA acceptance of its Biologics License Application for Imsidolimab, a treatment for Generalized Pustular Psoriasis (GPP). The company reported positive results from clinical trials, with over 50% of patients achieving clear or almost clear skin. VNDA shares rose nearly 5% in pre-market trading.